Pharmaceutical Preparations · DE · CIK 1817713
Developing novel immunotherapies using proprietary T cell engager and modulator platforms for cancer treatment
Comparable business profile · signals at a glance
In the 90 days to Jan 2, 2026: 6 sold $972K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Campbell David AlanPresident and CEO | Sell | 8,072 | $13.73 | $111K |
| Jan 2, 2026 | Mciver ZachariahChief Medical Officer | Sell | 2,714 | $13.73 | $37K |
| Jan 2, 2026 | Diraimondo ThomasChief Scientific Officer | Sell | 2,505 | $13.73 | $34K |
| Jan 2, 2026 | Winter Charles M.Chief Technical Officer | Sell | 2,401 | $13.73 | $33K |
| Jan 2, 2026 | Meyer Andrew HollmanChief Business Officer | Sell | 1,879 | $13.73 | $26K |
| Jan 2, 2026 | Dobek MariaVice President, Accounting | Sell | 1,462 | $13.73 | $20K |
| Dec 1, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 2,700 | $32.85 | $89K |
| Dec 1, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 633 | $33.52 | $21K |
| Nov 14, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 3,333 | $30.00 | $100K |
| Oct 28, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 16,665 | $30.06 | $501K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.